News
2 minute read

MBHB Partner Kevin Noonan Quoted in Gizmodo.com Article Entitled, "Why the Patent Battle Over CRISPR Matters (and Why It Doesn’t)"

Kevin E. Noonan, Ph.D.January 9, 2017

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a January 9, 2017 online edition of Gizmodo.com in an article entitled, “Why the Patent Battle Over CRISPR Matters (and Why It Doesn’t).” By the time a panel of judges at the U.S. Patent and Trademark Office gets around to deciding who owns the biggest biotechnology innovation of the century, CRISPR-Cas9 may have already lost its heavyweight title as the most precise tool for genetic engineering. View the article